NCT01603485View on ClinicalTrials.gov

Study to Estimate the Pharmacokinetics, Bioavailability and Effect of Food on Single Dose Modified-release Lersivirine 500 mg in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Healthy Volunteer
Interventions
DRUG

Lersivirine Immediate-Release (fasted)

Single 500 mg dose of Lersivirine Immediate-Release Tablets (2 x 250 mg)

DRUG

Lersivirine Modified-Release #1 (fasted)

Single 500 mg dose of Lersivirine Modified-Release Tablet #1

DRUG

Lersivirine Modified-Release #2 (fasted)

Single 500 mg dose of Lersivirine Modified-Release Tablet #2

DRUG

Lersivirine Modified-Release #3 (fasted)

Single 500 mg dose of Lersivirine Modified-Release Tablet #3

DRUG

Lersivirine Modified-Release (fed)

Single 500 mg dose of Lersivirine Modified-Release Tablet dosed with food.

Trial Locations (1)

B-1070

Pfizer Investigational Site, Brussels

Sponsors

Lead Sponsor

Pfizer

Collaborators (1)

ViiV Healthcare
All Listed Sponsors
collaborator

ViiV Healthcare

INDUSTRY

lead

Pfizer

INDUSTRY